Travere Therapeutics, Inc. (TVTX)
| Market Cap | 3.78B |
| Revenue (ttm) | 490.73M |
| Net Income (ttm) | -25.55M |
| Shares Out | 92.37M |
| EPS (ttm) | -0.29 |
| PE Ratio | n/a |
| Forward PE | 25.90 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,248,349 |
| Open | 40.97 |
| Previous Close | 40.81 |
| Day's Range | 40.75 - 42.08 |
| 52-Week Range | 13.88 - 43.31 |
| Beta | 0.87 |
| Analysts | Strong Buy |
| Price Target | 40.62 (-0.66%) |
| Earnings Date | May 4, 2026 |
About TVTX
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company’s products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urin... [Read more]
Financial Performance
In 2025, Travere Therapeutics's revenue was $490.73 million, an increase of 110.45% compared to the previous year's $233.18 million. Losses were -$25.55 million, -92.06% less than in 2024.
Financial StatementsAnalyst Forecast
According to 13 analysts, the average rating for TVTX stock is "Strong Buy." The 12-month stock price target is $40.62, which is a decrease of -0.66% from the latest price.
News
Travere Therapeutics to Report First Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced it will report first quarter 2026 financial results on Monday, May 4, 2026, after the close of the U.S. financial ...
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on April 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to f...
FDA Approval For Travere's Drug Expands Reach To Broader Rare Kidney Disease Patients
Travere Therapeutics is a biopharmaceutical company focused on developing therapies for rare kidney, liver, and metabolic diseases.
Travere Therapeutics Transcript: Study update
FILSPARI received FDA approval as the first therapy for FSGS without nephrotic syndrome, based on robust phase III data showing significant reductions in proteinuria and improved kidney outcomes. The launch leverages existing infrastructure, targets over 30,000 eligible US patients, and is expected to drive durable growth.
US FDA expands approval for Travere Therapeutics' drug for rare kidney disease
The U.S. Food and Drug Administration has approved the expanded use of Travere Therapeutics' drug to treat a rare kidney disorder, the company said on Monday.
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--U.S. FDA approves FILSPARI (sparsentan) for FSGS.
Travere Therapeutics Earnings Call Transcript: Q4 2025
Record 2025 revenue and patient growth driven by FILSPARI's strong adoption in IgA nephropathy, with continued momentum expected in 2026. Pipeline advanced with FSGS sNDA and pegtibatinase Phase 3, while financials strengthened by milestone payments and robust sales.
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update. “2025 marked a year of mea...
Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close...
Travere Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Significant progress was highlighted across rare disease programs, with FILSPARI showing strong commercial momentum in IgA nephropathy and an anticipated rapid launch in FSGS pending April FDA approval. The HCU program is restarting phase III, and the company remains financially strong with patent protection through 2033.
Travere Therapeutics to Present at the Guggenheim Emerging Outlook Biotech Summit
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, Februar...
TVTX: Travere Therapeutics Shareholders Should Contact Block & Leviton To Potentially Recover Losses
BOSTON, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Travere Therapeutics, Inc. (Nasdaq: TVTX) for potential securities law violations. Investors who have lost money in their Tra...
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Travere Therapeutics Announces FDA Extends Review of sNDA for FILSPARI® (sparsentan) in FSGS
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental N...
Travere Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Record growth achieved in rare kidney disease therapies, with FILSPARI showing strong clinical and commercial momentum in IgA nephropathy and promising data in FSGS. Regulatory engagement for FSGS is ongoing, and the HARMONY phase III study for pegtibatinase in HCU is restarting this quarter.
Travere Therapeutics Provides Corporate Update and 2026 Outlook
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the ...
Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthca...
Travere Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Key priorities include FILSPARI's strong launch in IgA nephropathy, an sNDA for FSGS with a potential broad label, and the restart of pegtibatinase's phase 3 trial for HCU. Physician and payer feedback supports broad access, and clinical programs are well-capitalized.
Travere Therapeutics Transcript: Jefferies London Healthcare Conference 2025
Management highlighted strong progress in rare kidney disease therapies, with FILSPARI's FSGS approval on track for January and robust commercial performance in IgA nephropathy. Financial position is solid, supporting continued pipeline execution and future growth.
Travere Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
Late-breaking data reinforced sparsentan's benefit in FSGS, with strong reduction in proteinuria and kidney failure risk. Regulatory review is on track for January, with a broad label requested and rapid launch expected. Financial position remains strong, supporting ongoing pipeline investments.
Travere Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Strong progress in rare kidney disease therapies, with an anticipated FSGS FDA decision in January and robust IgAN uptake. Financial position is solid, supporting ongoing R&D and commercial expansion, while pegtibatinase advances toward phase three restart.
Travere Therapeutics Announces Late-Breaking Data from Phase 3 DUPLEX Study of FILSPARI in FSGS Presented at the American Society of Nephrology (ASN) Kidney Week 2025
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced new data from the Phase 3 DUPLEX Study demonstrating that patients with focal segmental glomerulosclero...
Travere Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences: Guggenheim's 2nd Annual H...
Top 2 Health Care Stocks That May Fall Off A Cliff This Quarter
As of Oct. 31, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Travere Therapeutics Earnings Call Transcript: Q3 2025
Q3 saw robust revenue growth driven by FILSPARI's strong performance in IgA nephropathy, with net sales up over 155% year-over-year. The company is preparing for a potential FSGS launch, has strengthened its financial position, and continues to advance its pipeline.